Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Nakhlis F, et al. Among authors: overmoyer b. Breast Cancer Res Treat. 2024 Apr;204(2):289-297. doi: 10.1007/s10549-023-07195-5. Epub 2023 Dec 28. Breast Cancer Res Treat. 2024. PMID: 38155272
Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA. Isaacs C, et al. Among authors: overmoyer b. J Clin Oncol. 1997 Nov;15(11):3368-77. doi: 10.1200/JCO.1997.15.11.3368. J Clin Oncol. 1997. PMID: 9363868 Clinical Trial.
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel CL, Remick S. Cooney MM, et al. Among authors: overmoyer b. Cancer Chemother Pharmacol. 2005 Mar;55(3):295-300. doi: 10.1007/s00280-004-0871-5. Epub 2004 Nov 6. Cancer Chemother Pharmacol. 2005. PMID: 15538570 Clinical Trial.
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd. Storniolo AM, et al. Among authors: overmoyer b. J Clin Oncol. 2008 Jul 10;26(20):3317-23. doi: 10.1200/JCO.2007.13.5202. Epub 2008 May 19. J Clin Oncol. 2008. PMID: 18490651 Clinical Trial.
High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Barón AE, Purdy MH, Ross M, Jones RB. Bearman SI, et al. Among authors: overmoyer ba. Bone Marrow Transplant. 1997 Dec;20(11):931-7. doi: 10.1038/sj.bmt.1701000. Bone Marrow Transplant. 1997. PMID: 9422471 Clinical Trial.
113 results